|
Synonyms: compound (+)-16a [PMID: 25633969]
Compound class:
Synthetic organic
Comment: Lumocaserin is the INN for a serotonin 5-HT2C receptor agonist, with anti-epileptic potential. The structure provided in the INN record is identical to that for compound (+)-16a in [2], and additional 2-phenylcyclopropylmethylamine-based 5-HT2C agonists similar to lumocaserin are described in [3]. Analysis of available patent and peer-reviewed information around compounds with this core structural scaffold strongly suggests that lumocaserin is the INN for Bright Minds Biosciences' clinical candidate BMB-101, which is in development as an anti-epileptic agent. BMB-101 exhibits bias for Gq-mediated signaling. It does not induce β-arrestin recruitment and therefore does not cause 5-HT2C receptor desensitization.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| BMB-101 was progressed as a clinical candidate, primarily to evaluate it as a potential therapy for developmental and epileptic encephalopathies (DEEs) and drug-resistant absence seizures [1]. The FDA placed a partial hold on trial NCT06401538 in October 2026, due to issues around toxicity (in mice) and the lack of pharmacokinetic and juvenile toxicity data to support testing in paediatric patients. A clinical trial has been designed to test BMB-101's efficacy to reduce appetite and weight gain in patients with Prader-Willi syndrome. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05397041 | A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers | Phase 1 Interventional | Bright Minds Biosciences Pty Ltd | ||
| NCT06401538 | BMB-101 in Absence Epilepsy and DEE | Phase 2 Interventional | Bright Minds Biosciences Pty Ltd | ||
| NCT07266324 | A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome. | Phase 2 Interventional | Bright Minds Biosciences Pty Ltd | ||